Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign

Lippi, Giuseppe; Mattiuzzi, Camilla

doi:10.21203/rs.3.rs-1116534/v1

Cited by 2 publications

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants

Lippi

Adeli

Plebani

2021

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Measuring the level of protection conferred by anti-SARS-CoV-2 (trimeric) spike or RBD (receptor binding domain) antibodies (especially total and IgG) is a suitable and reliable approach for predicting biological protection against the risk of infection and severe coronavirus disease 2019 (COVID-19) illness. Nonetheless, SARS-CoV-2 has undergone a broad process of recombination since the identification of the prototype lineage in 2019, introducing a huge number of mutations in its genome and generating a vast array of variants of interest (VoI) and concern (VoC). Many of such variants developed several mutations in spike protein and RBD, with the new Omicron (B.1.1.529) clade displaying over 30 changes, 15 of which concentrated in the RBD. Besides their impact on virus biology, as well as on the risk of detection failure with some molecular techniques (i.e., S gene dropout), recent evidence suggests that these mutations may also jeopardize the reliability of currently available commercial immunoassays for detecting anti-SARS-CoV-2 antibodies. The antigen (either spike or RBD) and epitopes of the prototype SARS-CoV-2 coated in some immunoassays may no longer reflect the sequence of circulating variants. On the other hand, anti-SARS-CoV-2 antibodies elicited by highly mutated SARS-CoV-2 variants may no longer be efficiently recognized by the currently available commercial immunoassays. Therefore, beside the compelling need to regularly re-evaluate and revalidate all commercially available immunoassays against live virus neutralization assays based on emerging VoCs or VoIs, diagnostic companies may also consider to redevelop their methods, replacing former SARS-CoV-2 antigens and epitopes with those of the new variants.

show abstract

Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants

Lippi

Adeli

Plebani

2021

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

Estimate the long-term aversion effects and trade-offs of major health outcomes for the COVID-19 pandemic (Preprint)

Nakamoto,

Zhuang

2023

Preprint

View full text Add to dashboard Cite

BACKGROUND Vaccines have facilitated the substantial reduction and containment of COVID-19 transmission in many countries by early 2023. However, the long-term interconnection between vaccines, traits of the pathogen, vaccination strategies, and cases averted/trade-offs of health outcomes is not well understood. OBJECTIVE Estimate the long-term aversion effects and trade-offs of major health outcomes for the COVID-19 pandemic. METHODS Utilizing a compartment-calibrated model, I estimated the aversion/trade-offs effect on six major disease burdens (i.e., total/symptomatic/asymptomatic/hospitalized/ICU/death cases averted) over time conditional on a variety level of scenarios. RESULTS The findings implied that low-risk immunity profiles of booster doses increased the peak cases averted versus medium- and high-risk counterparts. The effect was most salient for the former paired with enhancing the rollout rate of doses, followed by the medium- and then high-risk scenarios. Positive and chronically durable aversion effects for the low-risk, in contrast, negative trade-offs and decreasing aversion effects for the suboptimal scenarios were observed. CONCLUSIONS Vaccination strategies, traits of pathogens, and traits of vaccines exert important roles in controlling the transmission of infectious diseases. While there are heterogeneities in vaccines, public strategies, social efforts, and other considerations, this work can provide an evidence-based rationale for the long-term trade-off analysis of vaccination and contribute to the sustainable containment of infectious diseases.

show abstract

Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign

Cited by 2 publications

References 2 publications

Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants

Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants

Estimate the long-term aversion effects and trade-offs of major health outcomes for the COVID-19 pandemic (Preprint)

Contact Info

Product

Resources

About